Rachna T. Shroff, MD, on Using Gemcitabine, Cisplatin, and Nab-paclitaxel to Treat Biliary Tract Cancers

Posted: Tuesday, January 31, 2023

Rachna T. Shroff, MD, of the University of Arizona Cancer Center, discusses the clinical implications of phase III results from the SWOG 1815 study, which suggest that adding nab-paclitaxel to gemcitabine and cisplatin may potentially benefit patients with locally advanced biliary tract or gallbladder cancer, findings that may warrant further evaluation. Ongoing biomarker analyses may identify other subsets of patients who might benefit from this fairly aggressive combination triplet.